Blue Cross moves to dismiss US antitrust claims over spinal fusions
MLex Summary: Blue Cross Blue Shield told a US federal judge that TranS1 cannot show that it conspired to keep it out of the market. BCBS argued that “the complaint does not...To view the full article, register now.
Already a subscriber? Click here to view full article